Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:ATOSNASDAQ:DYAINASDAQ:ENTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.24-5.3%$1.14$0.87▼$6.78$123.99M0.76859,037 shs954,610 shsATOSAtossa Therapeutics$0.83-4.4%$0.75$0.55▼$1.66$107.43M1.01785,994 shs608,937 shsDYAIDyadic International$1.00-5.2%$1.21$0.93▼$2.67$29.97M1.0168,700 shs26,173 shsENTAEnanta Pharmaceuticals$5.81+1.0%$5.42$4.09▼$17.24$124.20M0.81286,008 shs67,695 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-5.34%+1.64%+6.90%-33.69%-77.21%ATOSAtossa Therapeutics-4.39%-14.27%+12.70%+4.59%-45.64%DYAIDyadic International-5.16%-4.25%-17.70%-32.72%-45.88%ENTAEnanta Pharmaceuticals+1.04%+1.04%+3.75%-27.65%-54.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.604 of 5 stars3.12.00.04.52.01.70.6ATOSAtossa Therapeutics2.0287 of 5 stars3.52.00.00.03.11.70.0DYAIDyadic International2.538 of 5 stars3.55.00.00.00.01.70.0ENTAEnanta Pharmaceuticals3.8431 of 5 stars3.41.00.04.73.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00222.58% UpsideATOSAtossa Therapeutics 3.00Buy$7.13756.68% UpsideDYAIDyadic International 3.00Buy$6.00502.53% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25196.90% UpsideCurrent Analyst Ratings BreakdownLatest DYAI, ENTA, ATOS, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/21/2025ATOSAtossa TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.253/26/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/12/2025ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.502/27/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.40N/AN/A$1.41 per share0.88ATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ADYAIDyadic International$3.34M8.96N/AN/A$0.20 per share4.98ENTAEnanta Pharmaceuticals$64.46M1.93N/AN/A$5.24 per share1.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.26N/AN/AN/A-257.54%-108.77%-27.03%8/6/2025 (Estimated)ATOSAtossa Therapeutics-$30.09M-$0.21N/AN/AN/AN/A-35.74%-33.51%8/11/2025 (Estimated)DYAIDyadic International-$6.80M-$0.20N/AN/AN/A-188.09%-149.16%-59.81%8/12/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-157.57%-75.53%-27.30%8/4/2025 (Estimated)Latest DYAI, ENTA, ATOS, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/13/2025Q1 2025ATOSAtossa Therapeutics-$0.06-$0.05+$0.01-$0.05N/AN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million3/26/2025Q4 2024DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$1.60 million$0.82 million3/25/2025Q4 2024ATOSAtossa Therapeutics-$0.0633-$0.05+$0.0133-$0.05N/AN/A2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29ATOSAtossa TherapeuticsN/A13.3013.30DYAIDyadic International1.545.155.15ENTAEnanta PharmaceuticalsN/A5.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ATOSAtossa Therapeutics12.74%DYAIDyadic International27.95%ENTAEnanta Pharmaceuticals94.99%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%ATOSAtossa Therapeutics7.60%DYAIDyadic International29.50%ENTAEnanta Pharmaceuticals13.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableATOSAtossa Therapeutics8129.17 million116.24 millionOptionableDYAIDyadic International730.09 million21.07 millionOptionableENTAEnanta Pharmaceuticals16021.38 million18.37 millionOptionableDYAI, ENTA, ATOS, and ALEC HeadlinesRecent News About These CompaniesEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the ...May 24 at 6:48 PM | finanznachrichten.deD. E. Shaw & Co. Inc. Has $2.42 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 23 at 3:35 AM | marketbeat.com331,900 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Acquired by Stonepine Capital Management LLCMay 20, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires 98,285 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 19, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 17, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 15, 2025 | uk.finance.yahoo.comDoes Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?May 15, 2025 | zacks.comEnanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comEnanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to AnalystsMay 5, 2025 | insidermonkey.com1,038,000 Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Purchased by RA Capital Management L.P.May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Caligan Partners LPMay 3, 2025 | marketbeat.comBoothbay Fund Management LLC Has $492,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)May 3, 2025 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2025 | marketbeat.comEnanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Has $938,000 Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 30, 2025 | marketbeat.comMarshall Wace LLP Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)April 26, 2025 | marketbeat.comWhy Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.48%April 15, 2025 | aaii.comWhy Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 7.51%April 13, 2025 | aaii.comEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025April 8, 2025 | businesswire.comEnanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to ImmunologyMarch 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting Wrong3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Savvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs It Time to Buy the Dip in Novo Nordisk Stock?By Chris Markoch | May 15, 2025View Is It Time to Buy the Dip in Novo Nordisk Stock?Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsBy Jea Yu | April 29, 2025View Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsDYAI, ENTA, ATOS, and ALEC Company DescriptionsAlector NASDAQ:ALEC$1.24 -0.07 (-5.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.27 +0.03 (+2.82%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Atossa Therapeutics NASDAQ:ATOS$0.83 -0.04 (-4.39%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.84 +0.01 (+0.64%) As of 05/23/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Dyadic International NASDAQ:DYAI$1.00 -0.05 (-5.16%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.00 0.00 (-0.08%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Enanta Pharmaceuticals NASDAQ:ENTA$5.81 +0.06 (+1.04%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.80 -0.01 (-0.17%) As of 05/23/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
